Developing the world’s 1st scalable, end-to-end system for cost-efficient, sustainable cultivated pork meat production

全球粮食系统需要生产50%以上的粮食，以维持未来40年不断增长的人口，同时大幅减少温室气体（GHG）排放（社会市场基金会，2020年）。总排放量的14%来自畜牧业。如果整个价值链不发生变化，到2050年，这些排放量可能会增加30-40% （IPCC,2020）。人造肉（CM）可以是一种安全和可持续的替代动物养殖。猪肉是消费最广泛的肉类（联合国粮农组织，2020年）。据估计，养殖猪肉的温室气体排放量为-75%，土地需求为-72% （Good Food Institute，2021年）。虽然目前的生产成本比动物养殖产品高出100-10,000倍，但通过适当的规模化技术，价格可能在2030年之前达到具有竞争力的水平。这个行业的进展一直很缓慢，但在过去的十年里，CM已经从2013年第一个售价25万美元的汉堡发展到2023年在美国获得批准并在新加坡销售的养殖鸡。动物替代技术（AAT）是一家位于剑桥大学的B2B公司。我们正在为CM生产创建一个可扩展的端到端系统，包括专业的生物过程、启用技术和软件。我们的使命是使可持续粮食的获取民主化，并解决世界上最大的可持续性和粮食安全挑战。我们与Cellivate在这个研发项目中的合作旨在开发世界上第一个端到端、具有成本效益的养殖猪肉生产系统，使肉类生产商能够大规模地商业化生产他们自己定制的养殖猪肉产品，这些产品营养丰富，一般消费美味，对环境的影响更小，质量更高，更强大的本地供应链和道德来源。我们将通过优化和结合我们的非转基因细胞系与Cellivate专有的便宜10倍的无动物成分培养基和定制的可食用支架，在我们新颖的，可扩展的专用生物反应器中，然后扩大规模。到目前为止，我们已经从风投和战略投资者那里筹集了300万英镑，并开发了几项专利/开创性技术，包括细胞系和生物电子传感器。我们的工作获得了多个奖项，AAT参与了4个加速器。我们曾在TechCrunch、Food Navigator、The Spoon等网站上发表文章，专注于食品安全和可持续发展。Cellivate已经开发了纳米专利技术，使细胞生长得更好更快。他们的产品组合包括可食用支架，生物材料和无血清培养基，加速CM的发展。Cellivate在Good Food Institute的“2020年亚洲Alt 100”名单中。它获得了三井化学，ASPIRE实验室的奖项/认可，并在多个出版物和播客中得到了介绍。

Global food systems need to produce 50% more food to sustain growing populations over the next 40 years, whilst substantially reducing greenhouse gas (GHG) emissions (Social Market Foundation,2020). 14% of total emissions are attributable to animal farming. Without changes throughout the value chain, these emissions are likely to increase by 30-40% by 2050(IPCC,2020).Cultivated meat (CM) can be a safe and sustainable alternative to animal farming. Pork is the most widely consumed meat(UN-FAO,2020). Cultivated pork is estimated to have -75% GHG emissions and -72% land requirements(Good Food Institute,2021). While production costs are currently 100-10,000x higher than for animal-farmed products, with the right scale-up technologies, prices could reach a competitive point before 2030\. Progress in the industry has been slow, but in the last decade, CM has gone from its 1st burger costing \>$250,000 in 2013 to cultivated chicken being approved in the USA and sold in Singapore by 2023\.Animal Alternative Technologies(AAT) is a B2B company located at the University of Cambridge. We are creating a scalable, end-to-end system for CM production, including specialist bioprocesses, enabling technologies, and software. Our mission is to democratise access to sustainable food and tackle the world's biggest sustainability and food security challenges. Our collaboration with Cellivate during this R&D project aims to develop the world's 1st end-to-end, cost-efficient cultivated pork production system that enables meat producers to commercially manufacture at large scales their own tailored, cultivated pork products, which are nutritious, delicious for general consumption, with lower environmental impact, higher quality, stronger local supply chains, and ethical sources. We will do this by optimizing and combining our non-GMO cell lines with Cellivate's proprietary 10x cheaper animal-component-free media and customized edible scaffolds in our novel, scalable purpose-built bioreactors, and then scaling up.To date, we have raised \>£3 million from VCs and strategic investors, and have developed several patents/pioneering technologies, including cell lines and bioelectronic sensors. Our work has received multiple awards, and AAT has participated in 4 accelerators. We have been featured in TechCrunch, Food Navigator, The Spoon, etc., and are focused on food security and sustainability. Cellivate has developed patented nanotech technologies that enable cells to grow better and faster. Their portfolio includes edible scaffolds, biomaterials and serum-free media, which accelerate CM development. Cellivate was in the Good Food Institute's "2020 Asia Alt 100" list. It has received awards/recognition from Mitsui Chemicals, ASPIRE Labs and has been featured in multiple publications and podcasts.